Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;54(10):666-70.
doi: 10.4111/kju.2013.54.10.666. Epub 2013 Oct 15.

Are hypoechoic lesions on transrectal ultrasonography a marker for clinically significant prostate cancer?

Affiliations

Are hypoechoic lesions on transrectal ultrasonography a marker for clinically significant prostate cancer?

Tae Il Noh et al. Korean J Urol. 2013 Oct.

Abstract

Purpose: To investigate the relationship of transrectal ultrasound (TRUS) findings with the pathological characteristics of prostate cancer (PCa).

Materials and methods: The study was conducted retrospectively by analyzing the data for 970 patients who underwent prostate biopsies. Gleason scores and other clinical variables were compared between PCa patients with and without hypoechoic lesions on TRUS.

Results: Of the 970 patients, PCa was diagnosed in 291 (30%). Of these, high-grade PCa (Gleason score of 7 or more) was diagnosed in 190 (65%). The cancer detection rate was higher in patients with hypoechoic lesions (43.9%) than in those without hypoechoic lesions (21.4%, p<0.001). High-grade PCa was detected more often in patients with hypoechoic lesions than in those without hypoechoic lesions (p<0.001). Independent predictors for high-grade PCa by logistic regression analysis included hypoechoic lesions on TRUS and abnormal digital rectal examination findings.

Conclusions: Patients with PCa who had hypoechoic lesions on TRUS had more aggressive pathological disease than did those without lesions. Therefore, hypoechoic lesions on TRUS could be a marker for clinically significant PCa.

Keywords: Clinical marker; Prostate neoplasms; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Similar articles

Cited by

References

    1. Watanabe H, Igari D, Tanahasi Y, Harada K, Saito M. Development and application of new equipment for transrectal ultrasonography. J Clin Ultrasound. 1974;2:91–98. - PubMed
    1. Smith JA., Jr Transrectal ultrasonography for the detection and staging of carcinoma of the prostate. J Clin Ultrasound. 1996;24:455–461. - PubMed
    1. Langer JE. The current role of transrectal ultrasonography in the evaluation of prostate carcinoma. Semin Roentgenol. 1999;34:284–294. - PubMed
    1. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–732. - PMC - PubMed
    1. Hall RR. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Eur Urol. 1996;29(Suppl 2):24–26. - PubMed

LinkOut - more resources